Creative Planning increased its holdings in Crispr Therapeutics AG (NASDAQ:CRSP) by 8.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,604 shares of the company’s stock after purchasing an additional 1,228 shares during the period. Creative Planning’s holdings in Crispr Therapeutics were worth $950,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in CRSP. NEXT Financial Group Inc increased its position in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the last quarter. Coastal Investment Advisors Inc. bought a new stake in Crispr Therapeutics in the third quarter worth $26,000. Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in Crispr Therapeutics in the fourth quarter worth $26,000. Webster Bank N. A. bought a new stake in Crispr Therapeutics in the fourth quarter worth $26,000. Finally, Clear Harbor Asset Management LLC bought a new stake in Crispr Therapeutics in the fourth quarter worth $44,000. Institutional investors own 50.01% of the company’s stock.
CRSP has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and issued a $84.00 price target on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 16th. ValuEngine cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 3rd. BidaskClub cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. Finally, William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and an average target price of $75.95.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $465,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 48,618 shares of company stock worth $3,230,760 in the last quarter. Company insiders own 21.40% of the company’s stock.
CRSP stock opened at $52.32 on Friday. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics AG has a twelve month low of $29.92 and a twelve month high of $74.00. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -113.74 and a beta of 3.25. The firm’s fifty day simple moving average is $59.31 and its two-hundred day simple moving average is $52.83.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What is a support level?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.